Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2002 Jun;10(6):272–276.

DDDR pacing for symptomatic patients with hypertrophic obstructive cardiomyopathy

The first experience in the Netherlands with pacing in HOCM

HJ Achterberg, MG Scheffer, R van Mechelen, MJM Kofflard, FJ ten Cate
PMCID: PMC2499779  PMID: 25696108

Abstract

Background

Hypertrophic obstructive cardiomyopathy (HOCM) is a primary cardiac disorder with a heterogeneous expression. When medical therapy fails in patients with symptomatic HOCM, three additional therapeutic strategies exist: ventricular septal myectomy, alcohol-induced percutaneous transluminal septal myocardial ablation (PTSMA) of the first septal branch of the anterior descending artery and pacemaker implantation. In this paper we present the results of seven patients in whom a dual-chamber pacemaker was implanted to reduce the gradient in the left ventricular outflow tract (LVOT) and to relieve their symptoms.

Methods

In patients with drug refractory symptomatic HOCM, not eligible for surgery, pacemaker therapy was recommended. Symptomatic HOCM was defined as symptoms of angina and dyspnoea, functional class NYHA 3-4 and a resting LVOT gradient during Doppler echocardiography of more than 2.75 m/s (30 mmHg). In these patients, a dual-chamber pacemaker was implanted with a right ventricular lead positioned in the right ventricular apex and an atrial lead positioned in the right atrial appendage. In all patients the AV setting was programmed between 50 and 100 ms, using Doppler echocardiography to determine the optimal filling and to ensure ventricular capture.

Results

A statistically significant reduction of the LVOT gradient was observed in all patients. The pre-implantation gradient in the LVOT measured by Doppler echocardiography varied from 3-5.8 m/s with a mean of 4.7±1.1 m/s. The post-implantation gradient varied from 1.4-2.6 m/s with a mean of 1.9±0.4 m/s (p<0.001). Symptomatic improvement was present in all patients. NYHA functional class went from 3-4 (mean 3.1±0.5) pre-implantation to 1-2 mean (1.3±0.4) after implantation (p<0.001). During a mean follow-up of 2.3±1.1 years, the improvement in functional class was maintained.

Conclusion

Our preliminary results demonstrate that dual-chamber pacing is an effective and safe treatment for symptomatic patients with HOCM.

Keywords: DDDR pacing, hypertrophic obstructive cardiomyopathy

Full text

PDF
272

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cannon R. O., 3rd, McIntosh C. L., Schenke W. H., Maron B. J., Bonow R. O., Epstein S. E. Effect of surgical reduction of left ventricular outflow obstruction on hemodynamics, coronary flow, and myocardial metabolism in hypertrophic cardiomyopathy. Circulation. 1989 Apr;79(4):766–775. doi: 10.1161/01.cir.79.4.766. [DOI] [PubMed] [Google Scholar]
  2. Cannon R. O., 3rd, Tripodi D., Dilsizian V., Panza J. A., Fananapazir L. Results of permanent dual-chamber pacing in symptomatic nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 1994 Mar 15;73(8):571–576. doi: 10.1016/0002-9149(94)90336-0. [DOI] [PubMed] [Google Scholar]
  3. Deinum J., van Gool J. M., Kofflard M. J., ten Cate F. J., Danser A. H. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension. 2001 Dec 1;38(6):1278–1281. doi: 10.1161/hy1101.096114. [DOI] [PubMed] [Google Scholar]
  4. Faber L., Seggewiss H., Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998 Dec 1;98(22):2415–2421. doi: 10.1161/01.cir.98.22.2415. [DOI] [PubMed] [Google Scholar]
  5. Fananapazir L., Cannon R. O., 3rd, Tripodi D., Panza J. A. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. 1992 Jun;85(6):2149–2161. doi: 10.1161/01.cir.85.6.2149. [DOI] [PubMed] [Google Scholar]
  6. Fananapazir L., Epstein N. D., Curiel R. V., Panza J. A., Tripodi D., McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994 Dec;90(6):2731–2742. doi: 10.1161/01.cir.90.6.2731. [DOI] [PubMed] [Google Scholar]
  7. Fananapazir L., McAreavey D. Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol. 1998 Feb;31(2):259–264. doi: 10.1016/s0735-1097(97)00509-3. [DOI] [PubMed] [Google Scholar]
  8. Fananapazir L., Tracy C. M., Leon M. B., Winkler J. B., Cannon R. O., 3rd, Bonow R. O., Maron B. J., Epstein S. E. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989 Nov;80(5):1259–1268. doi: 10.1161/01.cir.80.5.1259. [DOI] [PubMed] [Google Scholar]
  9. Henein M. Y., O'Sullivan C. A., Ramzy I. S., Sigwart U., Gibson D. G. Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999 Oct;34(4):1117–1122. doi: 10.1016/s0735-1097(99)00332-0. [DOI] [PubMed] [Google Scholar]
  10. Jeanrenaud X., Goy J. J., Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992 May 30;339(8805):1318–1323. doi: 10.1016/0140-6736(92)91961-7. [DOI] [PubMed] [Google Scholar]
  11. Kappenberger L., Linde C., Daubert C., McKenna W., Meisel E., Sadoul N., Chojnowska L., Guize L., Gras D., Jeanrenaud X. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997 Aug;18(8):1249–1256. doi: 10.1093/oxfordjournals.eurheartj.a015435. [DOI] [PubMed] [Google Scholar]
  12. Kofflard M. J., van Herwerden L. A., Waldstein D. J., Ruygrok P., Boersma E., Taams M. A., Ten Cate F. J. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996 Jul;28(1):197–202. doi: 10.1016/0735-1097(96)00103-9. [DOI] [PubMed] [Google Scholar]
  13. Krams R., Kofflard M. J., Duncker D. J., Von Birgelen C., Carlier S., Kliffen M., ten Cate F. J., Serruys P. W. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 1998 Jan 27;97(3):230–233. doi: 10.1161/01.cir.97.3.230. [DOI] [PubMed] [Google Scholar]
  14. Linde C., Gadler F., Kappenberger L., Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. 1999 Mar 15;83(6):903–907. doi: 10.1016/s0002-9149(98)01065-0. [DOI] [PubMed] [Google Scholar]
  15. Maron B. J., Epstein S. E. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979 Jun;43(6):1242–1244. doi: 10.1016/0002-9149(79)90160-7. [DOI] [PubMed] [Google Scholar]
  16. Maron B. J., Nishimura R. A., McKenna W. J., Rakowski H., Josephson M. E., Kieval R. S. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999 Jun 8;99(22):2927–2933. doi: 10.1161/01.cir.99.22.2927. [DOI] [PubMed] [Google Scholar]
  17. McKenna W. J., Camm A. J. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation. 1989 Nov;80(5):1489–1492. doi: 10.1161/01.cir.80.5.1489. [DOI] [PubMed] [Google Scholar]
  18. Prinzen F. W., Hunter W. C., Wyman B. T., McVeigh E. R. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. J Am Coll Cardiol. 1999 May;33(6):1735–1742. doi: 10.1016/s0735-1097(99)00068-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Seggewiss H., Gleichmann U., Faber L., Fassbender D., Schmidt H. K., Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998 Feb;31(2):252–258. doi: 10.1016/s0735-1097(97)00508-1. [DOI] [PubMed] [Google Scholar]
  20. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995 Jul 22;346(8969):211–214. doi: 10.1016/s0140-6736(95)91267-3. [DOI] [PubMed] [Google Scholar]
  21. Tavel M. E., Fananapazir L., Goldschlager N. F. Hypertrophic obstructive cardiomyopathy: problems of management. Chest. 1997 Jul;112(1):262–264. doi: 10.1378/chest.112.1.262. [DOI] [PubMed] [Google Scholar]
  22. Wigle E. D. Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. Heart. 2001 Dec;86(6):709–714. doi: 10.1136/heart.86.6.709. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES